InvestSMART

Orthocell Limited (ASX: OCC) - Announcements

- Current share price for OCC : $0.680

ASX company news and announcements for Orthocell Limited (OCC) are delayed by 20 minutes from the time of their release between 7.30am and 7.30pm EDT and are in PDF format. All Orthocell Limited (OCC) ASX announcements deemed to be price sensitive will be highlighted with . If you are looking for ASX announcements for companies other than Orthocell Limited (OCC), please use our Company Announcements tool to search across all ASX-listed companies.

Latest company announcements for Orthocell Limited (OCC)

Search all Announcements
Market Cap ($m) Headline Release
date/time+		 Price at
release+		 Current
price+		 Gain/Loss View
$185 Half Yearly Report and Accounts 23 Feb 2018 7:33PM $0.330 $0.680 risen by 106.06%
$185 New Cell Factory Patent Granted in the US 22 Feb 2018 9:57AM $0.320 $0.680 risen by 112.50%
$185 Positive CelGro Study Results in ACL Reconstruction 5 Feb 2018 9:58AM $0.350 $0.680 risen by 94.29%
$185 Appendix 4C - quarterly 31 Jan 2018 7:12PM $0.350 $0.680 risen by 94.29%
$185 Orthocell Granted Canadian Tendon Regeneration Patent 31 Jan 2018 10:10AM $0.350 $0.680 risen by 94.29%
$185 Change in substantial holding MHZ 30 Jan 2018 8:21AM $0.345 $0.680 risen by 97.10%
$185 Change in substantial holding PA 19 Jan 2018 11:29AM $0.340 $0.680 risen by 100%
$185 Change in substantial holding SRV 19 Jan 2018 11:27AM $0.340 $0.680 risen by 100%
$185 Change in substantial holding MC 19 Jan 2018 11:26AM $0.340 $0.680 risen by 100%
$185 Change in substantial holding QXZ 19 Jan 2018 11:25AM $0.340 $0.680 risen by 100%
$185 New Patent for Suture-Less Repair of Soft Tissue Secured 18 Jan 2018 9:56AM $0.335 $0.680 risen by 102.99%
$185 Successful Completion of Share Purchase Plan 12 Jan 2018 11:36AM $0.345 $0.680 risen by 97.10%
$185 Appendix 3B 12 Jan 2018 11:32AM $0.345 $0.680 risen by 97.10%
$185 Orthocell featured at Biotech Showcase in San Francisco 9 Jan 2018 9:28AM $0.350 $0.680 risen by 94.29%
$185 50% Patient Treatment Milestone in Human Nerve Trial 2 Jan 2018 8:29AM $0.340 $0.680 risen by 100%
$185 Share Purchase Plan Closing Date Extended 28 Dec 2017 11:27AM $0.340 $0.680 risen by 100%
$185 Appendix 3B and Notice Under Section 708A 20 Dec 2017 6:30PM $0.335 $0.680 risen by 102.99%
$185 Invitation to Participate in Share Purchase Plan 15 Dec 2017 3:22PM $0.350 $0.680 risen by 94.29%
$185 Notice Under ASIC Class Order CO 09/425 15 Dec 2017 3:17PM $0.350 $0.680 risen by 94.29%
$185 Orthocell Granted European Tendon Regeneration Patent 15 Dec 2017 9:36AM $0.350 $0.680 risen by 94.29%
$185 Orthocell Featured in CommSec Executive Series Interview 14 Dec 2017 10:04AM $0.350 $0.680 risen by 94.29%
$185 Placement and Share Purchase Plan 13 Dec 2017 10:01AM $0.385 $0.680 risen by 76.62%
$185 Trading Halt 11 Dec 2017 9:16AM $0.385 $0.680 risen by 76.62%
$185 Ortho-ATI Case Study Publication 8 Dec 2017 10:32AM $0.380 $0.680 risen by 78.95%
$185 Orthocell Commences Treatment of its 1,000th Patient 7 Dec 2017 9:58AM $0.380 $0.680 risen by 78.95%

601 - 625 of 772 results

Page 25 of 31

  • + Company announcements and prices are delayed by least 20 minutes. Prices are indicative only.

DISCLOSURE: InvestSMART Group Limited employees may have an interest in the securities and managed funds displayed via this service. Please refer to our Financial Services Guide for more information.

Data shown on this website is sourced by Morningstar
© Morningstar. All rights reserved. Neither any Morningstar company nor any of their content providers guarantee the data or content contained herein to be accurate, complete or timely nor will they have any liability for its use or distribution. Any general advice has been prepared by Morningstar Australasia Pty Ltd (ABN: 95 090 665 544, AFSL: 240892) and/or Morningstar Research Limited, subsidiaries of Morningstar, Inc, without reference to your objectives, financial situation or needs. You should consider the advice in light of these matters and, if applicable, the relevant Product Disclosure Statement (in respect of Australian products) or Investment Statement (in respect of New Zealand products) before making any decision to invest. No Morningstar-affiliated company or any of their employees is providing you with personalised financial advice. To obtain advice tailored to your particular circumstances, please contact a professional financial adviser. Some material is copyright and published under licence from ASX Operations Pty Limited ACN 004 523 782 ("ASXO"). Data and content is provided for personal use only.